Previous 10 | Next 10 |
The $79 million that Vyndaqel contributed to Pfizer 's (NYSE: PFE) third-quarter revenue doesn't mean a whole lot to the pharmaceutical giant . It amounted to a whopping 0.6% of the company's overall revenue. But you can bet that executives at Alnylam Pharmaceuticals (NASDAQ: ALNY) , Ak...
BOSTON, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that the company has promoted Kyle Jenne to chief commercial officer. This promotion is part of Akcea’s strategy to expand our...
BOSTON, Oct. 22, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, November 5 th at 4:30 p.m. Eastern Time to discuss its third quarter 2019 financial results and r...
October 8, 2019 Palm Beach, FL – October 8, 2019 – Medical device manufacturing remains a strong market, driven by technological developments, an aging population, and increases in chronic and lifestyle diseases – trends that expand healthcare spending. W...
The top-rated mid-cap sectors are financials (First Financial Bankshares ( FFIN ), LegacyTexas Financial ( LTXB ), Legg Mason ( LM ), Assured Guaranty ( AGO )), utilities (Ormat Technologies ( ORA ), Avista ( AVA )), industrials (Simpson Manufacturing ( SSD ), MasTec ( MTZ ), Trex Company ( TR...
Stocks bounced between gains and losses Monday as investors await inflation data and Federal Reserve minutes later this week. The Dow Jones Industrial Average (DJINDICES: ^DJI) and the S&P 500 (SNPINDEX: ^GSPC) fell in the afternoon, led down by energy and consume...
Shares of Akcea Therapeutics (NASDAQ: AKCA) are up 30% at 12:25 p.m. EDT after the biotech announced a licensing deal for its drug candidate, AKCEA-ANGPTL3-Lrx, with Pfizer (NYSE: PFE) . Ionis Pharmaceuticals (NASDAQ: IONS) , which is still a majority owner of its spin-off Akcea, saw...
Biopharmaceutical stocks are moving higher Monday morning. Well, at least, AKCA stock and IONS stock are. Here’s why. AKCA Stock Skyrockets: New Licensing Agreement With Pfizer Inc. On Monday, October 7, Akcea Therapeutics (NASDAQ:AKCA), which is an affiliate of Ionis Pharma...
Gainers: Akcea Therapeutics (NASDAQ: AKCA ) +29% . Liquid Media Group (NASDAQ: YVR ) +24% . AgeX Therapeutics (NYSEMKT: AGE ) +20% . Sutro Biopharma (NASDAQ: STRO ) +19% . Livongo Health (NASDAQ: LVGO ) +15% . Motus GI Holdings (NASDAQ: MOTS ) +12% . Teekay Tankers (NYSE: TNK )...
Ionis Pharmaceuticals (NASDAQ: IONS ) affiliate Akcea Therapeutics (NASDAQ: AKCA ) inks an agreement with Pfizer (NYSE: PFE ) for global rights to antisense drug AKCEA-ANGPTL3-Lrx for certain cardiovascular and metabolic diseases. More news on: Ionis Pharmaceuticals, Inc., Akcea Therapeu...
News, Short Squeeze, Breakout and More Instantly...
Akcea Therapeutics Inc. Company Name:
AKCA Stock Symbol:
NASDAQ Market:
Akcea Therapeutics Inc. Website:
Ionis and Akcea win prestigious Prix Galien Award for TEGSEDI® (inotersen) as Best Biotechnology Product PR Newswire BOSTON and CARLSBAD, Calif., Oct. 30, 2020 BOSTON and CARLSBAD, Calif. , Oct. 30, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, In...
Ionis Pharmaceuticals completes acquisition of Akcea Therapeutics Transaction creates a stronger, more efficient company PR Newswire CARLSBAD, Calif., Oct. 12, 2020 CARLSBAD, Calif. , Oct. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS...
NEW YORK, NY / ACCESSWIRE / September 23, 2020 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Akcea Therapeutics, Inc. (NASDAQ: AKCA ), relating...